| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 5.449 | 5.760 | 11.233 | 1.071 | 4.409 |
| Total Income - EUR | - | - | - | - | - | 5.449 | 8.833 | 16.175 | 4.057 | 34.825 |
| Total Expenses - EUR | - | - | - | - | - | 9.395 | 12.495 | 18.582 | 14.681 | 36.191 |
| Gross Profit/Loss - EUR | - | - | - | - | - | -3.947 | -3.662 | -2.407 | -10.624 | -1.366 |
| Net Profit/Loss - EUR | - | - | - | - | - | -4.098 | -3.928 | -2.737 | -10.624 | -1.366 |
| Employees | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Novus Pharma Distribution S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 3.383 | 842 | 30.973 | 29.768 | 3.412 |
| Current Assets | - | - | - | - | - | 11.421 | 18.727 | 21.343 | 23.030 | 24.616 |
| Inventories | - | - | - | - | - | 0 | 0 | 5 | 19 | 6 |
| Receivables | - | - | - | - | - | 9.450 | 10.267 | 14.950 | 15.683 | 17.090 |
| Cash | - | - | - | - | - | 1.971 | 8.460 | 6.388 | 7.329 | 7.520 |
| Shareholders Funds | - | - | - | - | - | -4.017 | -7.856 | -10.617 | -21.086 | -22.334 |
| Social Capital | - | - | - | - | - | 81 | 79 | 79 | 202 | 201 |
| Debts | - | - | - | - | - | 19.061 | 27.425 | 62.986 | 73.884 | 50.362 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4619
|
|||||||||
Comments - Novus Pharma Distribution S.r.l.